0551 GMT February 24, 2020
Researchers have developed “a promising new drug” that uses a protein present in the foot-and-mouth disease virus to kill off tumors in the pancreas, yahoo.com reported.
Scientists hope that the results of the study, published in the journal Theranostics, could pave the way for new treatments for the disease which causes around 9,200 deaths every year.
Commenting on the research, Dr. Emily Farthing, senior research information manager at Cancer Research UK, said: “This early-stage research has developed a promising new drug that reduces the growth of pancreatic tumors in the lab.
“And with further research to see if it’s safe and effective for patients, we hope that this could one day offer new hope for people with this disease.”
Pancreatic cancer is the 11th most common cancer in the UK, according to Cancer Research UK.
Only one percent of people diagnosed with the disease are expected to survive for 10 years or more.
The researchers found that a protein fragment taken from the foot-and-mouth disease virus targets another protein, called ΑvΒ6, found on the surface of a majority of pancreatic cancer cells.
Working with drug companies AstraZeneca and ADC Therapeutics, the team combined the virus protein fragment with a highly potent drug, called tesirine, to target pancreatic cancer cells.
When mice with pancreatic cancer tumors were treated with the protein-drug combination, the tumors were completely killed.
The rodents that had ΑvΒ6-positive tumors were given a tiny dose of the protein-drug combination three times a week, which stopped the tumors growing completely.
But when the dose was increased and given twice a week, the researchers found all the tumors in mice were completely killed.
Professor John Marshall, from the Queen Mary University of London and the lead author on the study, said: “Foot-and-mouth disease virus uses ΑvΒ6 as a route to infect cattle, as the virus binds to this protein on a cow’s tongue.
“By testing pieces of the protein in the virus that attaches to ΑvΒ6, we’ve developed a route to deliver a drug specifically to pancreatic cancers.”
The team also used the protein-drug combination on human cancer cells in the lab.
Some of these cells had ΑvΒ6 on their surface while others did not.
The researchers found that cells with ΑvΒ6 responded well to the treatment, while the ΑvΒ6 negative cells needed much higher doses of the drug for the cells to be killed.
The team now plans to perform further protein-drug combination tests on mice before moving to clinical trials.
The research was funded by the UK national medical research charity Pancreatic Cancer Research Fund.